pembrolizumab as first-line therapy for recurrent/metastatic head and neck cancer
Published 2 years ago • 106 plays • Length 6:35Download video MP4
Download video MP3
Similar videos
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
6:38
pembrolizumab with chemotherapy as first line for metastatic cervical cancer
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
3:05
sequencing therapies for recurrent head and neck cancers
-
6:54
an overview of immunotherapy in head and neck cancer
-
6:17
pembrolizumab for head and neck cancer
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
7:03
lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
-
9:28
progression after next line of therapy following first-line immunotherapy for adv head & neck cancer
-
26:30
head and neck cancer treatment update: pembrolizumab, nivolumab and pd-l1 markers
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
2:19
cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible muc
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
6:51
pembrolizumab and nivolumab in recurrent hnscc
-
7:56
keynote-048: progression post next line for r/m hnscc
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
3:17
the development of immunotherapies in the treatment of relapsed metastatic head and neck cancer